The content is available as a PDF (358.3 KB).
Contributors: SB,TMN,BR: took part in treating the patient and preparing the manuscript; AVR: patient management and preparing the manuscript.
Funding: None
Competing interest: None stated.
References
- 1.RCPCH. Guidance — Paediatric multisystem inflammatory syndrome temporally associated with COVID-19.Available from: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19. Accessed May 02, 2020.
- 2.Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. Coronavirus Disease (COVID-19) in Children — What We Know So Far and What We Do Not?. Indian Pediatr.2020 Apr 9 [Epub ahead of print]. Available from:https://www.indianpediatrics.net/COVID29.03.2020/SA-00159.pdf. Accessed May 09, 2020. [DOI] [PMC free article] [PubMed]
- 3.Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020 May 07. [Epub ahead of print]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31094-1/fulltext. Accessed on May 09, 2020. [DOI] [PMC free article] [PubMed]
- 4.Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020 Apr 10. [Epub ahead of print]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194613/pdf/main.pdf. Accessed May 09, 2020. [DOI] [PMC free article] [PubMed]
- 5.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.ClinicalTrials.gov: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04320615. Accessed May 03, 2020.
- 8.Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID 19: A single center experience. J Med Virol. 2020 Apr 06 [Epub ahead of print]. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25801. Accessed May 9, 2020. [DOI] [PMC free article] [PubMed]